303 related articles for article (PubMed ID: 18840713)
1. Functional proteomic profiling of AML predicts response and survival.
Kornblau SM; Tibes R; Qiu YH; Chen W; Kantarjian HM; Andreeff M; Coombes KR; Mills GB
Blood; 2009 Jan; 113(1):154-64. PubMed ID: 18840713
[TBL] [Abstract][Full Text] [Related]
2. Analysis of FLT3-Activating Mutations in Patients With Acute Myelogenous Leukemia in Jordan: Association With FAB Subtypes and Identification of Subgroups With Poor Prognosis.
Halahleh K; Taqash A; Abdelkhaleq H; Manasrah M; Marie L; Al-Rabi K
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e588-e597. PubMed ID: 33811005
[TBL] [Abstract][Full Text] [Related]
3. Construction of protein profile classification model and screening of proteomic signature of acute leukemia.
Xu Y; Zhuo J; Duan Y; Shi B; Chen X; Zhang X; Xiao L; Lou J; Huang R; Zhang Q; Du X; Li M; Wang D; Shi D
Int J Clin Exp Pathol; 2014; 7(9):5569-81. PubMed ID: 25337199
[TBL] [Abstract][Full Text] [Related]
4. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
Kornblau SM; Vu HT; Ruvolo P; Estrov Z; O'Brien S; Cortes J; Kantarjian H; Andreeff M; May WS
Clin Cancer Res; 2000 Apr; 6(4):1401-9. PubMed ID: 10778970
[TBL] [Abstract][Full Text] [Related]
5. P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival.
Assi R; Gur HD; Loghavi S; Konoplev SN; Konopleva M; Daver N; Tashakori M; Kadia T; Routbort M; Salem A; Kanagal-Shamanna R; Quesada A; Jabbour EJ; Kornblau SM; Medeiros LJ; Kantarjian H; Khoury JD
Am J Hematol; 2018 Nov; 93(11):1376-1383. PubMed ID: 30117185
[TBL] [Abstract][Full Text] [Related]
6. Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia.
Quintás-Cardama A; Zhang N; Qiu YH; Post S; Creighton CJ; Cortes J; Coombes KR; Kornblau SM
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):115-127.e15. PubMed ID: 25248926
[TBL] [Abstract][Full Text] [Related]
7. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Haferlach T; Schoch C; Löffler H; Gassmann W; Kern W; Schnittger S; Fonatsch C; Ludwig WD; Wuchter C; Schlegelberger B; Staib P; Reichle A; Kubica U; Eimermacher H; Balleisen L; Grüneisen A; Haase D; Aul C; Karow J; Lengfelder E; Wörmann B; Heinecke A; Sauerland MC; Büchner T; Hiddemann W
J Clin Oncol; 2003 Jan; 21(2):256-65. PubMed ID: 12525517
[TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics.
Kornblau SM; Thall PF; Estrov Z; Walterscheid M; Patel S; Theriault A; Keating MJ; Kantarjian H; Estey E; Andreeff M
Clin Cancer Res; 1999 Jul; 5(7):1758-66. PubMed ID: 10430080
[TBL] [Abstract][Full Text] [Related]
9. Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia.
Kornblau SM; Singh N; Qiu Y; Chen W; Zhang N; Coombes KR
Clin Cancer Res; 2010 Mar; 16(6):1865-74. PubMed ID: 20215543
[TBL] [Abstract][Full Text] [Related]
10. Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity.
Yi H; Zeng D; Shen Z; Liao J; Wang X; Liu Y; Zhang X; Kong P
Oncotarget; 2016 Jun; 7(26):40387-40397. PubMed ID: 27248172
[TBL] [Abstract][Full Text] [Related]
11. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
Lauber C; Correia N; Trumpp A; Rieger MA; Dolnik A; Bullinger L; Roeder I; Seifert M
Sci Rep; 2020 Jul; 10(1):12761. PubMed ID: 32728112
[TBL] [Abstract][Full Text] [Related]
12. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia.
Xu ZJ; Ma JC; Zhou JD; Wen XM; Yao DM; Zhang W; Ji RB; Wu DH; Tang LJ; Deng ZQ; Qian J; Lin J
J Transl Med; 2019 Mar; 17(1):102. PubMed ID: 30922328
[TBL] [Abstract][Full Text] [Related]
13. Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse.
Hoff FW; Hu CW; Qutub AA; Qiu Y; Hornbaker MJ; Bueso-Ramos C; Abbas HA; Post SM; de Bont ESJM; Kornblau SM
Proteomics Clin Appl; 2019 Jul; 13(4):e1800133. PubMed ID: 30650251
[TBL] [Abstract][Full Text] [Related]
14. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients.
Tien FM; Hou HA; Tsai CH; Tang JL; Chen CY; Kuo YY; Li CC; Lin CT; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Tseng MH; Liu MC; Liu CW; Lin LI; Chou WC; Tien HF
Eur J Haematol; 2018 Jul; 101(1):86-94. PubMed ID: 29624746
[TBL] [Abstract][Full Text] [Related]
15. Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics.
Strunk CJ; Platzbecker U; Thiede C; Schaich M; Illmer T; Kang Z; Leahy P; Li C; Xie X; Laughlin MJ; Lazarus HM; Gerson SL; Bunting KD; Ehninger G; Tse W
Am J Hematol; 2009 May; 84(5):308-9. PubMed ID: 19396856
[TBL] [Abstract][Full Text] [Related]
16. Esterase D and gamma 1 actin level might predict results of induction therapy in patients with acute myeloid leukemia without and with maturation.
Kaźmierczak M; Luczak M; Lewandowski K; Handschuh L; Czyż A; Jarmuż M; Gniot M; Michalak M; Figlerowicz M; Komarnicki M
Med Oncol; 2013 Dec; 30(4):725. PubMed ID: 24085543
[TBL] [Abstract][Full Text] [Related]
17. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia.
Kornblau SM; McCue D; Singh N; Chen W; Estrov Z; Coombes KR
Blood; 2010 Nov; 116(20):4251-61. PubMed ID: 20679526
[TBL] [Abstract][Full Text] [Related]
18. Functional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational status.
Cesano A; Putta S; Rosen DB; Cohen AC; Gayko U; Mathi K; Woronicz J; Hawtin RE; Cripe L; Sun Z; Tallman MS; Paietta E
PLoS One; 2013; 8(2):e56714. PubMed ID: 23431389
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation.
Nagler A; Labopin M; Craddock C; Socié G; Yakoub-Agha I; Gedde-Dahl T; Niittyvuopio R; Byrne JL; Cornelissen JJ; Labussière-Wallet H; Arcese W; Milpied N; Esteve J; Canaani J; Mohty M
Am J Hematol; 2022 Mar; 97(3):274-282. PubMed ID: 34978724
[TBL] [Abstract][Full Text] [Related]
20. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
